Skip to main content
. 2018 Jul 5;2018:5070573. doi: 10.1155/2018/5070573

Figure 10.

Figure 10

Mechanism of PYR-41- and thalidomide-impaired DC cross-presentation. PYR-41 and thalidomide inhibit myddosome formation via reducing NF-κB activation. Decreased myddosome formation recruited less p97 and Sec61 from the ER toward the endosomes, leading to less internalized antigens exported to the cytosol to be degraded, resulting in a reduced cross-presentation and subsequent cross-priming.